Asset profile
stapokibart
Monoclonal antibody
Evidence outlook · lead readout
NCT06277765 · Atopic Dermatitis
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT06277765: In this randomized, double-blind, placebo-controlled Phase 3 trial in 180 adolescents with atopic dermatitis, significantly more patients receiving stapokibart achieved at least a 75% reduction in eczema severity at 18 weeks than those on placebo (73.9% vs 43%, a 30.5 percentage point difference).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
66 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 12 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Stapokibart: this drug | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | ||
| GS101 | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| Manfidokimab | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| QL2108 | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| Rademikibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| CKD-706 | Phase 1 | Monoclonal antibody | IL-4R-alpha | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | ||
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | ||
| Lebrikizumab (Ebglyss) | Approved | Monoclonal antibody | IL-13 | ||
| Nemolizumab (Nemluvio) | Approved | Monoclonal antibody | IL-31 receptor A | ||
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | ||
| Ruxolitinib | Approved | Small molecule | JAK1/2 | ||
| Tapinarof | Approved | Small molecule | Aryl hydrocarbon receptor, Aryl Hydrocarbon Receptor Agonist |
…and 51 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4)
December 2026 (4)
What to watch
What to watch
What to watch
What to watch
2027 (2)
2028 (2)
March 2028 (1)
What to watch
December 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.